軽度認知障害またはアルツハイマー病患者を対象としたLY3303560の研究

基本情報

NCT ID

NCT03019536

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

22

治験依頼者名

Eli Lilly and Company

概要

The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body. This study will last up to 65 weeks, not including screening. Screening is required within 90 days prior to the start of the study.

対象疾患

介入

依頼者（Sponsor）